Patents Assigned to Gilead Sciences, Inc.
  • LPA receptor antagonists and uses thereof
    Patent number: 11912686
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: February 27, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Brian P. Bestvater, Julie Farand, Doris T. Tang, Kin S. Yang
  • Cot modulators and methods of use thereof
    Patent number: 11905299
    Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: February 20, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Gayatri Balan, Chien-Hung Chou, Christopher T. Clark, Jeromy J. Cottell, Musong Kim, Thorsten A. Kirschberg, John O. Link, Gary Phillips, Scott D. Schroeder, Neil H. Squires, Kirk L. Stevens, James G. Taylor, William J. Watkins, Nathan E. Wright, Sheila M. Zipfel
  • Remdesivir treatment methods
    Patent number: 11903953
    Abstract: Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.
    Type: Grant
    Filed: March 30, 2023
    Date of Patent: February 20, 2024
    Assignee: Gilead Sciences, Inc.
    Inventor: Tomas Cihlar
  • Substituted 6-azabenzimidazole compounds
    Patent number: 11897878
    Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
    Type: Grant
    Filed: November 9, 2021
    Date of Patent: February 13, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L Cosman, Rao V. Kalla, Zachary A. Kasun, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Sundaramoorthi Swaminathan, Joshua J. Van Veldhuizen, Suet C Yeung, Jeff Zablocki
  • IKAROS zinc finger family degraders and uses thereof
    Patent number: 11897862
    Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.
    Type: Grant
    Filed: April 7, 2023
    Date of Patent: February 13, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Gayatri Balan, Peter A. Blomgren, Chen Chen, Julian A. Codelli, Zhimin Du, Musong Kim, Dorothée Saddier Axe, Gregg M. Schwarzwalder, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani, William J. Watkins, Brian M. Weist, Suet C. Yeung, Helen Yu
  • Interleukin-2 variant proteins fused to human IgG4 Fc and uses thereof
    Patent number: 11896648
    Abstract: Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2R? (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: February 13, 2024
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Manuel Baca, Sarah A. Gilmore, Hassan Javanbakht, Prasenjit K. Mukherjee
  • Substituted pyridotriazine compounds and uses thereof
    Patent number: 11897892
    Abstract: The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: February 13, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Anna E. Hurtley, Lan Jiang, Jiayao Li, David W. Lin, Michael L. Mitchell, Devan Naduthambi, Gregg M. Schwarzwalder, Suzanne M. Szewczyk, Matthew J. Von Bargen, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
  • Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections
    Patent number: 11883397
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein L, R1, R5, W, X, Y1, Y2, and Z are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: January 30, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Manoj C. Desai, Mingzhe Ji, Haolun Jin, Hyung-Jung Pyun, Teresa Alejandra Trejo Martin
  • Inhibitors of peptidylarginine deiminases
    Patent number: 11878965
    Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: January 23, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Daniel H. Byun, Zhenhong R. Cai, Eda Y. Canales, Laurent P. Debien, Timothy R. Hansen, Richard Huang, Petr Jansa, Rick A. Lee, Jennifer A. Loyer-Drew, Ryan McFadden, Michael L. Mitchell, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Joshua J. Van Veldhuizen, Lianhong Xu
  • GLP-1R modulating compounds
    Patent number: 11858918
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: January 2, 2024
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Megan K. Armstrong, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, David W. Lin, Michael L. Mitchell, Ezra Roberts, Scott D. Schroeder, Nathan D. Shapiro, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • 1?-cyano nucleoside analogs and methods for treatment of viral infections
    Patent number: 11851438
    Abstract: 1?-Cyano nucleoside analogs of Formula I and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: March 6, 2023
    Date of Patent: December 26, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Daniel H. Byun, Yifan Deng, Jennifer L. Cosman Ellis, Rao V. Kalla, Richard L. Mackman, Dustin S. Siegel, Xianhuang Zeng
  • GLP-1R modulating compounds
    Patent number: 11851419
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: December 26, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Gediminas J. Brizgys, James S. Cassidy, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang
  • Solid forms of an HIV capsid inhibitor
    Patent number: 11845739
    Abstract: The present disclosure relates to pharmaceutically acceptable salts, cocrystals, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yOpyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: December 19, 2023
    Assignee: Gilead Sciences, Inc.
    Inventor: Bing Shi
  • Process for preparing a Cot inhibitor compound
    Patent number: 11845737
    Abstract: Disclosed are syntheses of a Cot (cancer Osaka thyroid) inhibitor, which has the following formula:
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: December 19, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Kevin M. Allan, Lina Chan, Andrei Chtchemelinine, Jeffrey T. Deignan, Kassibla E. Dempah, Kelly J. Eberle, Danielle M. Elfgren, Timothy G. Elford, Kevin D. Haggerty, Jesse W. Li, Tianmin Niu, Andrew C. Stevens, Ana F. Voica, Kevin S. Williamson, Boran Xu, Guojun Yu
  • Compounds and methods for treatment of viral infections
    Patent number: 11845755
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: March 6, 2023
    Date of Patent: December 19, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Daniel H. Byun, Yifan Deng, Jennifer L. Cosman Ellis, Rao V. Kalla, Richard L. Mackman, Dustin S. Siegel, Xianhuang Zeng
  • Diacylglycerol kinase modulating compounds
    Patent number: 11845723
    Abstract: The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: December 19, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Masaaki Sawa, Mai Arai, Ryoko Nakai, Hirokazu Matsumoto, Catherine Pugh, Eric Hu, Juan Guerrero, Jesse Jacobsen, Jonathan William Medley, Jie Xu, Latesh Lad, Leena Patel, Michael Graupe, Qingming Zhu, Stephen Holmbo, Tetsuya Kobayashi, Will Watkins, Yasamin Moazami, Suet C. Yeung, Julian A. Codelli, Heath A. Weaver
  • Choline salt forms of an HIV capsid inhibitor
    Patent number: 11833143
    Abstract: The present disclosure relates to choline salts, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfony)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)- 3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment and prevention of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: December 5, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Travis Lee Houston, Bing Shi
  • Methods of treating liver disease
    Patent number: 11833150
    Abstract: The present disclosure relates to a method of preventing and/or treating liver disease comprising administering an ACC inhibitor in combination with an FXR agonist to a patient in need thereof.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: December 5, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Jamie Geier Bates, David Gordon Clarkson Breckenridge, John T. Liles
  • Toll like receptor modulator compounds
    Patent number: 11827609
    Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: November 28, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Gregory Chin, Richard L. Mackman, Michael R. Mish, Jeff Zablocki
  • Cot modulators and methods of use thereof
    Patent number: 11827662
    Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
    Type: Grant
    Filed: April 7, 2022
    Date of Patent: November 28, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Eda Y. Canales, Manoj C. Desai, Eric Gorman, Jiayao Li, Roland D. Saito, James G. Taylor, Nathan E. Wright